BioCentury
ARTICLE | Clinical News

ACH-3102: Additional Phase II data

February 16, 2015 8:00 AM UTC

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 6 weeks led to an SVR 12 weeks after the end of treatment in 100% of patients. Additionally, all 12 patients who received ACH-3102 plus Sovaldi for 8 weeks achieved an SVR 24 weeks after the end of treatment. Achillion has previously reported data from the trial (see BioCentury, Aug. 18, 2014; Oct. 13, 2014; Nov. 17, 2014 & Jan. 5, 2015). ...